The company provides customized respiratory disease models for evaluating drug efficacy and endpoint measurements in diseases like Asthma, COPD, and cough. Their capabilities include target validation, in vitro and in vivo profiling, and pharmacological assessment of key biomarkers. IR Pharma serves the biopharma and pharma industries, offering a range of models and tests to evaluate respiratory drugs. They specialize in specific disease models for asthma, disease cough, and chronic obstructive pulmonary diseases, providing a system-based discovery platform that adds value to client lead compounds and technology.